A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation factor 15 (GDF-15) can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors.
from Medical Xpress - latest medical and health news stories https://ift.tt/OcNSzCR
